QQQ   292.59 (+1.69%)
AAPL   143.49 (+1.15%)
MSFT   247.06 (+2.68%)
META   147.04 (+3.92%)
GOOGL   97.36 (+2.25%)
AMZN   98.69 (+1.55%)
TSLA   159.50 (+10.43%)
NVDA   196.70 (+1.80%)
NIO   12.13 (+4.30%)
BABA   120.61 (+0.30%)
AMD   74.66 (-0.33%)
T   19.93 (-2.40%)
MU   62.48 (+1.53%)
F   12.90 (+0.86%)
CGC   2.74 (-0.72%)
GE   81.21 (+0.52%)
DIS   109.38 (+1.17%)
AMC   5.24 (-1.69%)
PFE   44.17 (-2.00%)
PYPL   80.39 (+1.63%)
NFLX   365.01 (-0.80%)
QQQ   292.59 (+1.69%)
AAPL   143.49 (+1.15%)
MSFT   247.06 (+2.68%)
META   147.04 (+3.92%)
GOOGL   97.36 (+2.25%)
AMZN   98.69 (+1.55%)
TSLA   159.50 (+10.43%)
NVDA   196.70 (+1.80%)
NIO   12.13 (+4.30%)
BABA   120.61 (+0.30%)
AMD   74.66 (-0.33%)
T   19.93 (-2.40%)
MU   62.48 (+1.53%)
F   12.90 (+0.86%)
CGC   2.74 (-0.72%)
GE   81.21 (+0.52%)
DIS   109.38 (+1.17%)
AMC   5.24 (-1.69%)
PFE   44.17 (-2.00%)
PYPL   80.39 (+1.63%)
NFLX   365.01 (-0.80%)
QQQ   292.59 (+1.69%)
AAPL   143.49 (+1.15%)
MSFT   247.06 (+2.68%)
META   147.04 (+3.92%)
GOOGL   97.36 (+2.25%)
AMZN   98.69 (+1.55%)
TSLA   159.50 (+10.43%)
NVDA   196.70 (+1.80%)
NIO   12.13 (+4.30%)
BABA   120.61 (+0.30%)
AMD   74.66 (-0.33%)
T   19.93 (-2.40%)
MU   62.48 (+1.53%)
F   12.90 (+0.86%)
CGC   2.74 (-0.72%)
GE   81.21 (+0.52%)
DIS   109.38 (+1.17%)
AMC   5.24 (-1.69%)
PFE   44.17 (-2.00%)
PYPL   80.39 (+1.63%)
NFLX   365.01 (-0.80%)
QQQ   292.59 (+1.69%)
AAPL   143.49 (+1.15%)
MSFT   247.06 (+2.68%)
META   147.04 (+3.92%)
GOOGL   97.36 (+2.25%)
AMZN   98.69 (+1.55%)
TSLA   159.50 (+10.43%)
NVDA   196.70 (+1.80%)
NIO   12.13 (+4.30%)
BABA   120.61 (+0.30%)
AMD   74.66 (-0.33%)
T   19.93 (-2.40%)
MU   62.48 (+1.53%)
F   12.90 (+0.86%)
CGC   2.74 (-0.72%)
GE   81.21 (+0.52%)
DIS   109.38 (+1.17%)
AMC   5.24 (-1.69%)
PFE   44.17 (-2.00%)
PYPL   80.39 (+1.63%)
NFLX   365.01 (-0.80%)
NASDAQ:CFRX

ContraFect - CFRX Stock Forecast, Price & News

$0.09
-0.01 (-8.49%)
(As of 01/26/2023 04:01 PM ET)
Add
Compare
Today's Range
$0.09
$0.10
50-Day Range
$0.09
$0.18
52-Week Range
$0.08
$4.54
Volume
19.78 million shs
Average Volume
19.90 million shs
Market Capitalization
$4.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

ContraFect MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
3,143.2% Upside
$3.00 Price Target
Short Interest
Healthy
2.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of ContraFect in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.43) to ($1.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars


CFRX stock logo

About ContraFect (NASDAQ:CFRX) Stock

ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

CFRX Stock News Headlines

ContraFect (NASDAQ:CFRX) Coverage Initiated at StockNews.com
Apple, Amazon, and Walmart are Investing in Solar Energy
The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
Apple, Amazon, and Walmart are Investing in Solar Energy
The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
ContraFect Retreats on Publication
ContraFect Cuts Workforce After Trial Setback
ContraFect: Q2 Earnings Insights - Benzinga
See More Headlines
Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

CFRX Company Calendar

Last Earnings
11/14/2022
Today
1/26/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CFRX
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+3,175.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-20,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.26 per share

Miscellaneous

Free Float
41,831,000
Market Cap
$4.00 million
Optionable
Not Optionable
Beta
0.50

Key Executives

  • Roger J. Pomerantz
    Chairman, President & Chief Executive Officer
  • Michael Messinger
    Chief Financial Officer
  • Raymond Schuch
    Vice President-Research
  • Gary Woodnutt
    Senior Vice President-Translational Services
  • Matthew Salamone
    Vice President-Human Resources













CFRX Stock - Frequently Asked Questions

Should I buy or sell ContraFect stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 3 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CFRX shares.
View CFRX analyst ratings
or view top-rated stocks.

What is ContraFect's stock price forecast for 2023?

4 analysts have issued 12 month price targets for ContraFect's shares. Their CFRX share price forecasts range from $1.00 to $7.00. On average, they expect the company's share price to reach $3.00 in the next year. This suggests a possible upside of 3,057.9% from the stock's current price.
View analysts price targets for CFRX
or view top-rated stocks among Wall Street analysts.

How have CFRX shares performed in 2023?

ContraFect's stock was trading at $0.0960 at the beginning of the year. Since then, CFRX stock has decreased by 1.0% and is now trading at $0.0950.
View the best growth stocks for 2023 here
.

Are investors shorting ContraFect?

ContraFect saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,050,000 shares, an increase of 153.4% from the December 31st total of 414,300 shares. Based on an average daily volume of 6,130,000 shares, the days-to-cover ratio is currently 0.2 days.
View ContraFect's Short Interest
.

When is ContraFect's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our CFRX earnings forecast
.

How were ContraFect's earnings last quarter?

ContraFect Co. (NASDAQ:CFRX) released its quarterly earnings results on Monday, November, 14th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.20.

When did ContraFect's stock split?

Shares of ContraFect reverse split on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

Who are ContraFect's major shareholders?

ContraFect's stock is owned by a number of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of ContraFect?

Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $0.10.

How much money does ContraFect make?

ContraFect (NASDAQ:CFRX) has a market capitalization of $4.15 million. The biotechnology company earns $-20,280,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The official website for the company is www.contrafect.com. The biotechnology company can be reached via phone at (914) 207-2300 or via email at mmessinger@contrafect.com.

This page (NASDAQ:CFRX) was last updated on 1/26/2023 by MarketBeat.com Staff